Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Video courtesy of NIHR

On International Clinical Trials Day, the RECOVERY Trial team are reflecting on an unprecedented collaboration that has seen over 10,000 patients enrolled in the world’s largest trial of potential COVID-19 treatments.

20 May is the anniversary of recruitment into what is thought to be the first clinical trial in 1747. At a time when scurvy was rife among seamen, James Lind, then a surgeon’s mate on the HMS Salisbury, followed a hunch that it was caused by putrefaction of the body. Lind noted that ‘No physician conversant with this disease at sea had undertaken to throw light upon the subject’. He recruited 12 sailors and allocated two men to each of six different treatments (vinegar, nutmeg, oranges and lemons, sea water, cider, and elixir of vitriol) and found that those given oranges and lemons experienced ‘the most sudden and good visible effects.’

273 years later, clinical research at Oxford University is at the forefront of global efforts to tackle the coronavirus pandemic. The RECOVERY Trial is the world’s biggest trial of potential COVID-19 treatments and the fastest ever recruiting individually randomised controlled trial. It was set up in record time, taking just nine days from conception to launch, and has recruited over 10,000 patients in 176 UK hospitals in just two months.

Read the full story on the RECOVERY Trial website

Read more about how the RECOVERY Trial was set-up

Similar stories

Oxford spinout Optellum secures $14m funding to advance pioneering AI-powered lung cancer diagnosis technology

Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.

New study shows higher rate of fractures in people with intellectual disability

In the most comprehensive study of its kind, researchers at the University of Oxford and Oxford Health NHS Foundation Trust found a substantially higher rate of fractures in people with intellectual disability compared with people of the same age and gender without an intellectual disability.

New evidence for how our brains handle surprise

A new study from the Bruno Group is challenging our perceptions of how the different regions of the cerebral cortex function. A group of ‘quiet’ cells in the somatosensory cortex that rarely respond to touch have been found to react mainly to surprising circumstances. The results suggest their function is not necessarily driven by touch, but may indicate an important and previously unidentified role across all the major cortices.

Language learning difficulties in children linked to brain differences

A new study using MRI has revealed structural brain changes in children with developmental language disorder (DLD), a common but under-recognised difficulty in language learning. Children with DLD aged 10-15 showed reduced levels of myelin in areas of the brain associated with speaking and listening to others, and areas involved in learning new skills. This finding is a significant advance in our understanding of DLD and these brain differences may explain the poorer language outcomes in this group.

The Gene Therapists Headline at Glastonbury 2022

Rosie Munday writes about her experience taking science to the masses at the Glastonbury Festival.